{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '1.', 'Persons aged >12 years if receiving primary two-dose mRNA COVID-19 vaccine series', 'or persons aged >18 years if receiving a third mRNA COVID-19 vaccine dose according', 'to FDA authorization or approval and ACIP recommendation. Note: receipt of an mRNA', 'COVID-19 vaccine within 8 hours of enrollment is permitted', '2. English or Spanish literate', '3. Intention of receiving influenza vaccine and mRNA COVID-19 vaccine based on ACIP-', 'CDC guidelines', '4. Willing to provide written informed consent', '5. Intention of being available for entire study period and complete all relevant study', 'procedures, including follow-up phone calls and clinic visits', '4.2 Subject Exclusion Criteria', 'Subjects who meet any of the following criteria will not be eligible to participate in this', 'study:', '1. Currently pregnant, planning to become pregnant within the first three months of the', 'study per participant self-report or likely to be pregnant per screening criteria as defined', 'in Section 5.1 at Visit 1', '2.', 'Prior receipt of IIV4 during the 2021-2022 influenza season', '3. Prior receipt of non-mRNA COVID-19 vaccine', '4. Prior receipt of more than 2 mRNA COVID-19 vaccines', '5. Documented COVID-19 infection within 6 weeks prior to enrollment confirmed by either', 'medical history or lab testing', '6. History of severe allergic reaction after a previous dose of any influenza vaccine; or to', 'an influenza vaccine component, including egg protein', '7. History of severe adverse reaction associated with a vaccine and/or severe allergic', 'reaction (e.g. anaphylaxis) to any component of an mRNA vaccine', '8. Receipt of any licensed inactivated vaccine within 2 weeks prior to enrollment in this', 'study, receipt of any licensed live vaccine within 4 weeks prior to enrollment in this', 'study, or receipt of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) or HEPLISAV-B', '(Hepatitis B Vaccine (Recombinant), Adjuvanted) vaccine within 6 weeks prior to', 'enrollment in this study or planning receipt of any vaccines following enrollment until 6', 'weeks after receipt of the second dose of mRNA COVID-19 vaccine', '9. Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate', 'cancer that is stable in the absence of therapy) or a history of any hematologic', 'malignancy*', '*Participants with a history of malignancy may be included if, after previous treatment by', 'surgical excision, chemotherapy or radiation therapy, the participant has been observed', \"for a period that in the investigator's estimation provides a reasonable assurance of\", 'sustained cure', '10. Thrombocytopenia, bleeding disorder, or anticoagulant use contraindicating', 'intramuscular injection (a daily aspirin may be acceptable).', '11. Has immunosuppression as a result of an underlying illness or medications, such as', 'antirejection/transplant regimens or immunomodulatory agents. Stable HIV disease is', 'permitted per the following parameters:', 'a. Confirmed stable HIV disease defined as document viral load <50 copies/mL and', 'CD4 count >200 within 6 months before enrollment, and on stable antiretroviral', 'therapy for at least 6 months', '23']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '12. Has known hepatitis B (HBV) or hepatitis C (HBC). Stable HBV or HBC are permitted', 'per the following parameters:', 'a. If known HBV: confirmed inactive chronic HBV infection: HBsAg present for >6', 'months and HBeAg negative, anti-HBe positive; serum HBV DNA <2000 IU/mL;', 'persistently normal ALT or AST levels; in those who had liver biopsy, findings', 'that confirm absence of significant necroinflammation', 'b. If known HCV: evidence of sustained virological response for >12 weeks after', 'treatment or without evidence of HCV RNA viremia (undetectable HCV RNA)', '13. Use of oral, parenteral, or high-dose inhaled glucocorticoids*', '*For definition of high-dose inhaled glucocorticoids, reference Appendix B.', '14. History of Guillain-Barr\u00e9 syndrome', '15. Anyone who is already enrolled or plans to enroll in another clinical trial with an', 'investigational product during the study period.', '*Per protocol, co-enrollment in observational or behavioral intervention studies are', 'permitted at any time. An investigational product may be permitted for therapy of an', 'illness condition that occurs during the study period e.g. COVID-19 illness.', '16. Hearing loss determined by the investigators to prevent successful communication over', 'the phone', '17. History of myocarditis or pericarditis', '18. History of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A).', '19. Has injury or other reason why deltoid site on both arms cannot be used for', 'vaccinations.', '20. Any condition which, in the opinion of the investigators, may pose a health risk to the', 'subject or interfere with the evaluation of the study objectives.', '21. Anyone who is a relative of any research study personnel.', '22. Anyone who is an employee of any research study personnel.', '4.3 Temporary Delay Criteria (Visit 1, 2 and 3 (for primary COVID-19 vaccine series))', '1. History of febrile illness (> 100.0\u00b0F or 37.8\u00b0C) within the past 72 hours prior to vaccine', 'administration', '4.4 Recruitment', 'Potential participants >12 years of age will be recruited from several sources at Duke University', 'Medical Center (DUMC), Johns Hopkins University (JHU), and Cincinnati using varying', 'techniques. Study investigators will enroll at least 450 persons over one influenza season', '(2021-2022). Approximately 160 will be enrolled at Duke, 160 will be enrolled at Johns Hopkins,', \"and 130 at Cincinnati Children's Hospital.\", 'The general techniques for how subjects will be recruited include the following: Study staff,', 'including Pls and clinical research coordinators will approach patients seen during clinic visits', 'about the study; notify other health care professionals in their health system about the study via', 'letters and flyers for potential referrals; notify potential subjects about the study via study', 'registries and recruitment service programs. More specific mechanisms to DUMC, JHU, and', 'Cincinnati are described below. In addition, research staff will work with local COVID-19', 'vaccination clinics to recruit study participants.', 'At DUMC, we will plan to enroll persons for whom the COVID-19 vaccine is recommended by', 'the ACIP. Duke will plan to work with Duke Employee Health and Wellness (OEHW) to identify', '24']\n\n###\n\n", "completion": "END"}